UroGen Pharma Ltd. Quarterly Net Income (Loss) Attributable to Parent in USD from Q1 2017 to Q2 2024
-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
-
Summary
-
UroGen Pharma Ltd. quarterly/annual Net Income (Loss) Attributable to Parent history and growth rate from Q1 2017 to Q2 2024.
- UroGen Pharma Ltd. Net Income (Loss) Attributable to Parent for the quarter ending June 30, 2024 was -$33.4M, a 38.4% decline year-over-year.
- UroGen Pharma Ltd. Net Income (Loss) Attributable to Parent for the twelve months ending June 30, 2024 was -$114M, a 4.16% decline year-over-year.
- UroGen Pharma Ltd. annual Net Income (Loss) Attributable to Parent for 2023 was -$102M, a 6.87% increase from 2022.
- UroGen Pharma Ltd. annual Net Income (Loss) Attributable to Parent for 2022 was -$110M, a 0.94% increase from 2021.
- UroGen Pharma Ltd. annual Net Income (Loss) Attributable to Parent for 2021 was -$111M, a 13.7% increase from 2020.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Quarterly (USD)
Net Income (Loss) Attributable to Parent, YoY Quarterly Growth (%)